CN1935212A - Chinese medicine preparation for treating gastrosia - Google Patents
Chinese medicine preparation for treating gastrosia Download PDFInfo
- Publication number
- CN1935212A CN1935212A CN 200610200880 CN200610200880A CN1935212A CN 1935212 A CN1935212 A CN 1935212A CN 200610200880 CN200610200880 CN 200610200880 CN 200610200880 A CN200610200880 A CN 200610200880A CN 1935212 A CN1935212 A CN 1935212A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- preparation
- group
- medicine preparation
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 71
- 239000003814 drug Substances 0.000 title claims abstract description 69
- 206010000087 Abdominal pain upper Diseases 0.000 claims abstract description 17
- 241000133430 Tinospora Species 0.000 claims abstract description 3
- 239000002775 capsule Substances 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 10
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 235000019634 flavors Nutrition 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 241000978490 Bistorta Species 0.000 claims description 2
- 241001078983 Tetradium ruticarpum Species 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 3
- 241000587240 Cynanchum Species 0.000 abstract 1
- 241000633855 Litsea pungens Species 0.000 abstract 1
- 241000205407 Polygonum Species 0.000 abstract 1
- 244000237957 Schisandra propinqua Species 0.000 abstract 1
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 20
- 230000000694 effects Effects 0.000 description 15
- 210000002784 stomach Anatomy 0.000 description 15
- 230000003203 everyday effect Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 230000037396 body weight Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 208000007107 Stomach Ulcer Diseases 0.000 description 10
- 201000005917 gastric ulcer Diseases 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 208000025865 Ulcer Diseases 0.000 description 9
- 231100000397 ulcer Toxicity 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- 210000004051 gastric juice Anatomy 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 229960004373 acetylcholine Drugs 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000012567 medical material Substances 0.000 description 6
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000012449 Kunming mouse Methods 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 208000000114 Pain Threshold Diseases 0.000 description 5
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 5
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 229960000935 dehydrated alcohol Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000037040 pain threshold Effects 0.000 description 5
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 5
- 229960003147 reserpine Drugs 0.000 description 5
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010022998 Irritability Diseases 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 210000002318 cardia Anatomy 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 230000000762 glandular Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 229940100691 oral capsule Drugs 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- BBFQZRXNYIEMAW-UHFFFAOYSA-N aristolochic acid I Chemical compound C1=C([N+]([O-])=O)C2=C(C(O)=O)C=C3OCOC3=C2C2=C1C(OC)=CC=C2 BBFQZRXNYIEMAW-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
- 229960001380 cimetidine Drugs 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000891 anti-reserpine Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a Chinese medicine preparation for curing stomach-ache. Said Chinese medicine preparation is made up by using six Chinese medicinal materials of schisandra propinqua, litsea pungens, paniculate cynanchum, evodia fruit, tinospora tuber and polygonum bistorate through a certain preparation process. Said invention can obtain obvious therapeutic effect for curing stomach-ache.
Description
Technical field: the present invention relates to a kind of Chinese medicine preparation for the treatment of stomachache, belong to technical field of Chinese medicines.
Background technology: to the patent ZL02134138.9 of State Intellectual Property Office application and patent power in, by Caulis Kadsurae Longipedunculatae, JIUYUE life, Radix Cynanchi Paniculati, Fructus Evodiae, Radix Tinosporae, Rhizoma Bistortae Six-element Chinese medicine made by compound capsule for treating stomachache for the applicant.The Semen Oroxyli section medical material but the JIUYUE life is born in the year of horse, according to " State Food and Drug Administration's " food medicine prison is annotated [2004] No. 379; about strengthening the notice of 6 kinds of medical materials such as Radix Aristolochiae Fangchi and preparation supervision and management thereof "; be to guarantee people's drug safety; according to the report that contains Aristolochic Acid medical material and preparation untoward reaction thereof and toxic and side effects research and result's analysis; decision is strengthened containing the supervision and management of Aristolochic Acid medical material and preparation thereof, guidance ability safety clothes usefulness that must the adhere rigidly to doctor.Therefore, in order to adapt to the demand of extensive patients, and guarantee patient's drug safety the JIUYUE life in the former compound capsule for treating stomachache to be replaced with safe medical material.
Summary of the invention:
The objective of the invention is to: a kind of Chinese medicine preparation for the treatment of stomachache is provided.The present invention is research experiment on the basis of former compound capsule for treating stomachache, successfully the JIUYUE life is replaced with safe medical material, and its good effect has no side effect, and cost is low, can adapt to the demand of extensive patients, and can guarantee patient's drug safety.
The present invention constitutes like this: the Chinese medicine preparation that it is made by Caulis Kadsurae Longipedunculatae, Fructus cinnamomi camphorae, Radix Cynanchi Paniculati, Fructus Evodiae, Radix Tinosporae, Rhizoma Bistortae Six-element Chinese medicine; Each Chinese medicine of distinguishing the flavor of is respectively by weight: Caulis Kadsurae Longipedunculatae 30-50 part, Fructus cinnamomi camphorae 35-60 part, Radix Cynanchi Paniculati 5-15 part, Fructus Evodiae 5-15 part, Radix Tinosporae 3-15 part, Rhizoma Bistortae 3-15 part.
Specifically, each Chinese medicine of distinguishing the flavor of is respectively by weight: 40 parts of Caulis Kadsurae Longipedunculatae, 47 parts of Fructus cinnamomi camphoraes, 10 parts of Radix Cynanchi Paniculatis, 10 parts of Fructus Evodiaes, 8 parts of Radix Tinosporaes, 8 parts of Rhizoma Bistortaes.
Described Chinese medicine preparation is a said dosage form on any pharmaceutics.
Described Chinese medicine preparation is capsule preferably, and the Chinese medicine powder of soon respectively distinguishing the flavor of is broken into fine powder, gets product after incapsulating according to the processing technology of conventional capsule behind the mixing.
Compare with former patent ZL02134138.9, the present invention cures mainly close with function the JIUYUE raw medicinal herbs and Fructus cinnamomi camphorae that have no side effect is replaced.Preparation avirulence of the present invention after prescription changes, drug effect and former compound capsule for treating stomachache do not have significant difference, take safe and reliable; Has promoting flow of QI and blood, the function of dispersing cold for relieving pain can be used for treating the gastral cavilty twinge due to the QI stagnated by cold blood stasis, the heating installation acid regurgitation, symptoms such as inappetence, and be used for the treatment of superficial gastritis, atrophic gastritis, stomachache, gastric ulcer, duodenal ulcer etc. and see above-mentioned disease person.The invention belongs to Miao Ethnomedicine series, safety non-toxic, gastrointestinal is double to be controlled, and analgesic effect is good, and helicobacter pylori is had inhibitory action, and gastroenteropathys such as digestive tract ulcer, chronic gastritis, stomachache are had curative effect preferably.
For further verifying the effect of preparation of the present invention, the applicant has carried out series of experimental research, and is specific as follows:
One, pharmacodynamics test
Purpose:, compare the two main pharmacodynamics, so that the clinical practice foundation to be provided by former compound capsule for treating stomachache and preparation of the present invention are carried out zoopery.
1 experiment material
1.1 medicine is subjected to the reagent thing: preparation of the present invention is provided lot number 20040601 by Guizhou Wansheng Pharmaceutical Co., Ltd..The oral capsule dosage form, every heavy 0.35g of dress, suitable crude drug 0.35g, adult every day 2 times, each 2-3 grain becomes body weight for humans press 60kg and calculates, and it is clinical that to draft the each every day consumption of being grown up be 0.035g/kg.Be mixed with the variable concentrations suspension with distilled water during experiment, refrigerator is preserved standby.
Former compound capsule for treating stomachache preparation (being called for short former preparation), provide by Guizhou Wansheng Pharmaceutical Co., Ltd., lot number (20031001), the oral capsule dosage form, every the heavy 0.28g of dress, quite crude drug 0.28g, adult every day 2 times, each 2-3 grain becomes body weight for humans press 60kg and calculates, and clinical to draft the each every day consumption of being grown up be 0.028g/kg.Be mixed with the variable concentrations suspension with distilled water during experiment, refrigerator is preserved standby.
Positive control drug: cimetidine capsule, provide by the southern part of the country, Guangdong medicine company limited, lot number 20040201, oral capsule, every heavy 0.2g of dress, adult every day 2 times, each 1, become body weight for humans press 60kg calculating, clinical Coming-of-Age Day consumption be 0.007g/kg, be mixed with suspension with distilled water during experiment, refrigerator is preserved standby.
Reagent: acetylcholine (Ach), reserpine, dehydrated alcohol provide by pharmacology teaching and research room of Guiyang College of Traditional Chinese Medicine.
1.2 the big ear rabbit of animal Japan, ♀ ♂ dual-purpose, body weight 3.0 ± 0.5kg; The wistar rat, ♀ ♂ half and half, body weight 230 ± 20g; Kunming mice, ♀ ♂ dual-purpose, body weight 20 ± 2g provides by the Guiyang Medical College Experimental Animal Center.
1.3 instrument
Isolated organ tester Zhao Shanghai experimental apparatus factory produces
LMS-2B type two road physiology monitors are produced by Chengdu Instruement Factory
The muscular tension transducer is produced by shellfish section equipment company limited
GJ-8402 hot plate dolorimeter Zhao Shanghai instrument plant produces
2 experimental techniques and result;
2.1 preparation of the present invention causes the influence that the rabbit myenteron shrinks to ACh
2.1.1 sample preparations
Get body weight 3.0 ± 0.5kg rabbit, ♀ ♂ is regardless of, and taps the head and puts to death back taking-up duodenum rapidly, puts into tyrode's solution surface plate (constantly towards oxygen) is housed, be cut into the segment of 2.0cm, a line and knotting are respectively worn in two ends, and a termination specimen plate is put into 37 ℃ of thermostatic baths that contain the 10.0ml tyrode's solution, last termination muscular tension transducer, tension force 1.0g, every 20min changes one time of nutrition liquid, begins experiment behind the balance 1h.
2.1.2 method
Specimen is divided into normal saline (NS) normal control group, heavy dose of the present invention, middle dosage, small dose group, former preparation group, positive drug (cimetidine) matched group, every group of every specimen at first writes down one section normal (not adding any medicine) myenteron autonomic movement curve and adds a certain amount of ACh again, shrinking appears in myenteron strengthens even spasm, add various a certain amount of reagents that are subjected to immediately respectively, the myenteron performance is lax, washes then 3 times, treat that myenteron recovers just often, add a certain amount of reagent that is subjected to, add the same dosage ACh immediately, observe flesh intestinal contractility weakened at different degrees, the results are shown in Table 1, the result shows that the present invention is big, middle dosage and former preparation all can be alleviated the muscular spasm effect.
Table 1 preparation of the present invention to acetylcholine (ACh) cause rabbit exsomatize enterospasm the scape influence (X ± s, n=10)
| Group | Dosage (g/kg) | Sample number (n) | Shrinkage amplitude (mm) | Suppress percentage rate (%) |
| The former preparation group of dosage group small dose group of the present invention positive drug control group among the present invention of the heavy dose of group of Normal group the present invention | - 0.0336 0.0168 0.0064 0.0128 0.0300 | 6 3 3 6 6 3 | 29075±3.77 15.13±3.40** 16.88±4.70** 24.50±4.08 18.13±3.91** 22.88±7.26 | - 49.14 43.26 17.65 39.06 23.09 |
Annotate: compare * p＜0.05 * * p＜0.01 with the normal group matched group
2.2 preparation analgesic activity of the present invention
Get 60 of Kunming mouses 2.2.1 chemical substance-acetic acid is caused the influence (writhing method) of mice pain, be divided into the normal control group at random, the large, medium and small dosage group of the present invention, former preparation group, positive drug control group.Press ig (filling stomach) administration respectively of table 2 drug dose, once a day, continuous three times, 1h behind the last medicine, lumbar injection (ip) 0.6% acetum 0.2ml/ only, write down every Mus every Mus writhing response number of times in writhing response incubation period and the 15min takes place, the results are shown in Table 2, the result shows that preparation of the present invention and former preparation all have the pain caused effect of the acetic acid of inhibition.
Table 2 preparation Dichlorodiphenyl Acetate of the present invention cause mouse writhing reaction influence (X ± s, n=10)
| Group | Dosage (g/kg) | Writhing response incubation period (min) | Writhing response number of times (15min) |
| The former preparation group of dosage group small dose group of the present invention positive drug control group among the present invention of the heavy dose of group of normal control group the present invention | 0.672 0.336 0.168 0.336 0.070 | 3.5±0.8 6.1±2.28* 5.7±2.75* 5.8±2.75* 5.9±2.56* 4.3±1.57 | 32.3±12.53 13.9±9.3** 13.2±10.4** 14.5±8.9** 14.9±8.0** 19.1±10.32* |
Annotate: compare * p＜0.05 * * p＜0.01 with the normal group matched group
2.2.2 stimulate the influence (hot plate method) that causes mice pain to adopt the GJ-8402 dolorimeter to filter out 60 of the ♀ Kunming mouse of pain threshold values between 5～30s to hot plate, be divided into 6 groups (with experimental projects 2.2) at random and at first measure normal (not administration) pain threshold of every group of each Mus, press table 2 drug dose ig administration then, every day 1 time, continuous 3 days, 0.5h behind the last medicine, 1.5h, 3h, 6h measures respectively and respectively organizes each Mus pain threshold (s), the results are shown in Table 3.1, table 3.2, show that preparation of the present invention and former preparation all have analgesic activity, the present invention is big, middle dosage is close with former preparation effect.
Table 3.1 preparation of the present invention to hot plate stimulate the influence cause mice pain (X ± s, n=10)
| Group | Dosage (g/kg) | Pain threshold (s) before the medicine | Pain threshold behind the medicine (s) | |||
| 0.5h | 1.5h | 3h | 6h | |||
| The former preparation group of dosage group small dose group of the present invention positive drug control group among the present invention of the heavy dose of group of Normal group the present invention | - 0.672 0.336 0.168 0.336 0.070 | 19.2±4.37 19.4±4.74 19.1±4.38 17.4±5.19 18.4±4.50 16.9±5.00 | 19.3±4.37 25.5±3.27** 27.4±6.38** 22.6±5.90 22.8±4.57* 21.3±46.01 | 19.9±3.21 28.9±4.41** 29.3±7.75** 24.2±4.78* 31.9±5.49** 240±4.88* | 18.4±3.13 26.4±4.53** 26.3±8.74* 23.0±3.06* 25.7±5.48** 24.1±4.07** | 18.3±3.89 24.8±3.88* 21.7±5.54 21.5±4.81 24.1±7.39 23.1±5.28* |
Table 3.2 preparation of the present invention to hot plate stimulate the influence cause mice pain (X ± s, n=10)
| Group | Dosage (g/kg) | Improve analgesia percentage rate (%) | |||
| 0.5h | 1.5h | 3h | 6h | ||
| The former preparation group of dosage group small dose group of the present invention positive drug control group among the present invention of the heavy dose of group of normal control group the present invention | - 0.672 0.336 0.168 0.335 0.070 | - 31.4±10.31 43.5±14.70 29.9±21.50 23.9±12.70 26.0±10.10 | - 49.0±15.72 53.4±15.90 39.1±19.60 73.4±30.50 42.0±21.74 | - 36.1±16.33 37.7±18.68 32.2±12.30 39.7±31.21 16.0±19.16 | - 30.9±11.28 13.6±5.83 24.0±26.6 31.0±26.10 36.7±12.00 |
2.3 anti-gastric-ulcer effect
2.3.1 water logging irritability is caused the influence of mouse gastric ulcer
60 of Kunming mouses are divided into 6 groups at random: the ulcer model group, and the present invention is big, in, small dose group, former preparation group, positive drug control group, every group of 10 mices, ♀ ♂ half and half, press table 4 drug dose ig administration, model group ig Isodose distilled water once a day, continuous 5 times, 1h is bundled in mice respectively on the special iron wire net rack after the last ig administration, then each Mus is placed (23 ± 0.5 ℃) in the same water tank, do not disturb mutually between each Mus, the depth of water is to the xiphoid-process place, 24h takes out animal, take off neck and put to death, open the abdominal cavity, ligation cardia and pylorus, and inject 1% formalin 1ml to gastric, stomach cut be immersed in 10% formalin, 30min takes out, and cuts off stomach along greater gastric curvature, observing glandular stomach portion ulcer counts, the statistics ulcer index the results are shown in Table 4, shows that preparation of the present invention and former preparation all have the effect of the water logging of inhibition stress gastric ulcer.
Table 4 preparation of the present invention to water logging irritability cause mouse gastric ulcer influence (X ± s, n=10)
| Group | Dosage (g/kg) | Ulcer index | Ulcer generation percentage rate (%) |
| The former preparation group of dosage group small dose group of the present invention positive drug control group among the present invention of the heavy dose of group of model group the present invention | - 0.672 0.336 0.168 0.336 0.070 | 25.1±5.51 17.3±4.47** 18.7±4.47* 21.5±3.78 18.3±3.62* 19.7±5.08* | 100.0 31.08 25.50 14.34 27.09 21.51 |
2.3.2 reserpine is caused the influence of mice ulcer
60 of laboratory mices, ♀ ♂ half and half, random packet ig administration and administration number of times be all with experimental project 2.3.1,1h subcutaneous injection (sc) reserpine 10mg/kg behind the last medicine,
Take off cervical vertebra behind the 8h and put to death, cut open and get the Mus stomach, the fixing observation glandular stomach portion ulcer that reaches of specimen is counted with experimental project 3.1, the results are shown in Table 5, shows that preparation of the present invention and former preparation all have tangible anti-reserpine to cause the gastric ulcer effect.
Table 5 pair reserpine cause mouse gastric ulcer influence (X ± s, n=10)
| Group | Dosage (g/kg) | Ulcer is counted |
| The former preparation group of dosage group small dose group of the present invention positive drug control group among the present invention of the heavy dose of group of model control group the present invention | - 0.672 0.336 0.168 0.336 0.070 | 8.5±4.72 3.3±1.34** 4.3±2.87* 5.8±2.39* 4.9±1.91* 3.8±1.03* |
Annotate: compare * p＜0.05 * * p＜0.01 with model control group
2.3.3 dehydrated alcohol is caused the influence of rat gastric ulcer
60 of wistar rats; random packet is with experimental project 2.3.2; press table 6 drug dose ig administration; once a day; continuous 4 days; 3h behind the last medicine, ig dehydrated alcohol 0.5ml/ only dissect behind the 1h and get stomach; ligation cardia and pylorus; inject 1% formalin 5ml to gastric, cut stomach and put into 10% formalin, 1h tailing edge greater gastric curvature is cut off stomach and is observed glandular stomach portion gastric mucosa injury situation; results model group gastric mucosa of rat is white in color and all comes off; other are respectively organized rat pipe film injury and obviously alleviate, and show that the present invention is big; in; low dose causes gastric mucosa injury to dehydrated alcohol significant protective effect, and former preparation and positive drug all have this effect.
2.4 to rat gastric juice, gastric acid, pepsic influence
60 of wistar rats are divided into 6 groups at random with experimental project 2.2, press table 6 medicine
Dosage ig administration, every day 1 time, continuous 7 times, fasting can't help drinking 24h behind the last medicine, penta crust ratio
Appropriate sodium 30mg/kg, ip anesthesia, the ligation pylorus is administered once respectively in duodenum portion, the ligation cardia, get stomach, incline and gastric content, be collected in the graduated centrifuge tube,, accurately write down the gastric juice amount with the centrifugal 10min of 1500rpm speed, survey the gastric content pH value with precision pH reagent paper, get supernatant gastric juice 1ml, 1 of distilled water 2ml, phenolphthalein indicator, with 0.01molM NaOH titration to terminal, record exhausts the amount of NaOH, calculates total acidity gastric juice (amount of the NaOH of total acidity=exhaust), total acid output (total acid output=total acidity * gastric juice amount).Press the Mett method and measure pepsin activity, the results are shown in Table 6, show that each dosage group of preparation of the present invention, former preparation group and positive drug group compare no significant difference with the normal control group.
The table 6 pair excretory influence of rat gastric juice (X ± s, n=10)
| Group | Dosage (g/kg) | Gastric juice amount (ml) | Total acidity (mmol/L) | Total acid output (mmol/L.h) | Pepsin activity (μ g/ml.min) |
| Of the present invention group of former preparation group positive drug group of normal control group | - 0.47 0.24 0.12 0.24 0.049 | 5.44±1.65 4.04±1.88 4.29±1.20 5.62±1.84 5.13±1.62 4.08±1.85 | 3.11±1.09 2.94±1.37 2.76±1.39 3.61±1.81 3.18±1.35 2.91±1.81 | 16.91±11.86 11.86±9.33 11.84±5 69 20.30±11.76 16.33±7.70 11.86±9.61 | 468.1±117.50 408.3±154.10 440.4±120.50 563.3±162.20 436.0±154.20 395.2±139.30 |
Conclusion: above-mentioned experimental result confirms that preparation of the present invention can trivial solution removes acetylcholine and cause the rabbit myenteron and shrink the spasm effect, chemical substance-acetic acid and hot plate is stimulated bring out the mice pain model significant analgesia role is arranged; Water logging irritability is caused gastric ulcer, reserpine to be caused mouse gastric ulcer and dehydrated alcohol and causes the rat stomach mucosa injury significant protective effect is arranged.Not obvious to rat gastric juice, gastric acid, pepsic influence.Above experimental result provides the modern science foundation for the clinical practice of preparation of the present invention.
Two, acute toxicity test
Purpose: after observing preparation short-term orally give animal of the present invention, toxic reaction that is produced and death condition or maximum dosage or calculate clinical adult's consumption safety multiple, the safety of this medicine of overall merit.
1 experiment material
1.1 be subjected to reagent thing preparation of the present invention that lot number is provided by Guizhou Wansheng Pharmaceutical Co., Ltd.: 20040601, capsule formulation, every heavy 0.35g of dress drafts clinical daily dosage and is every day 2 times, each 2-3 grain, become body weight for humans press 60kg calculating, every day 0.035g/kg.
1.2 the laboratory animal mice, the Kunming kind, cleaning level, body weight 20 ± 2g, ♀ ♂ half and half is provided by the Guiyang Medical College Experimental Animal Center, the quality certification number: 040614.Give raising conforming in 3 days earlier, experimentized in the 4th day.
1.3 the experiment medicine preparation: will be subjected to reagent composite capsule content to be mixed with white suspension with distilled water, concentration is 0.16g/ml, be put in deposit in the refrigerator standby.
2 experimental techniques
2.1 6 of mices are got in the prerun experiment, give mice with 16% preparation of the present invention and once irritate stomach 0.4ml/10g body weight (closing the 20g/kg body weight), be equivalent to 256 times of adult's dosage every day (0.0336g/kg), observed 7 days, do not cause dead mouse, can not measure the median lethal dose(LD 50) (LD50) of medicine, so carry out this preparation maximum dosage-feeding determination test.
2.2 formal experiment
20 of Kunming mouses, ♀ ♂ half and half, fasting (can't help water) gave mice 16% preparation content suspension 0.4ml/10g body weight of the present invention and irritates stomach 1 time in 24h in 12 hours.This dosage is equivalent to 256 times of adult's dosage every day 0.0336g/kg according to the weight, raises 7 days mice is conventional after the administration, observes the mice performance day by day.
3 experimental results
Remove after the administration animal behind the mice medicine in 7 days and transient activity occurs and reduce, do not like bite, ingest outside, do not see that the toxic reaction and the phenomena of mortality appear in animal.This result shows that giving mice in 24 hours irritates stomach preparation of the present invention 1 time, observes not cause animal dead in 7 days.Mice can tolerate preparation content 6.4g/kg of the present invention according to the weight, is equivalent to draft 256 times of clinical adult's dosage every day (0.0336g/kg), and unlikely death.According to document (Xu Shuyun etc. edit pharmacological experimental methodology, Beijing: People's Health Publisher, 1982,412) report " it is then safer more than 100 times to it is generally acknowledged that according to the weight the mice maximum tolerated dose is equivalent to people's consumption, and clinic trial can be provided ".Therefore can think that preparation oral administration of the present invention is very little to the acute toxicity of animal, safety can provide clinic trial.
Conclusion:
Be subjected to drug level and volumetrical restriction, can't measure LD50 to 1 gastric infusion of mice, maximum dosage-feeding is 6.4g/kg after measured, be equivalent to 256 times of clinical application amount, through observing the no abnormal reaction of animal in 7 days, no death condition, so can think that the acute toxicity of this preparation is low, oral safety.
Three, study on the stability
Packaged preparation three batch samples of the present invention were tested 3 months under low temperature accelerated test condition, taken a sample down in the room temperature storage condition every index is measured, test result shows that preparation of the present invention is surveyed every index and met tentative standard, steady quality.Therefore determine that its effect duration is 36 months.
The specific embodiment:
Embodiments of the invention 1: get Caulis Kadsurae Longipedunculatae 40 grams, Fructus cinnamomi camphorae 47 grams, Radix Cynanchi Paniculati 10 grams, Fructus Evodiae 10 grams, Radix Tinosporae 8 grams, Rhizoma Bistortae 8 grams, each flavor Chinese medicine powder is broken into fine powder, sieves, behind the mixing, granulation, during capsule processing technology routinely incapsulates, every capsules loading amount is 0.35 gram, promptly gets capsule of the present invention.This preparation oral, adult every day 2 times, each 2-3 grain.
Embodiments of the invention 2: get Caulis Kadsurae Longipedunculatae 30 grams, Fructus cinnamomi camphorae 35 grams, Radix Cynanchi Paniculati 5 grams, Fructus Evodiae 5 grams, Radix Tinosporae 3 grams, Rhizoma Bistortae 3 grams, each flavor Chinese medicine powder is broken into fine powder, sieves, behind the mixing, granulation, during capsule processing technology routinely incapsulates, every capsules loading amount is 0.35 gram, promptly gets capsule.
Embodiments of the invention 3: get Caulis Kadsurae Longipedunculatae 50 grams, Fructus cinnamomi camphorae 60 grams, Radix Cynanchi Paniculati 15 grams, Fructus Evodiae 15 grams, Radix Tinosporae 15 grams, Rhizoma Bistortae 15 grams, each flavor Chinese medicine powder is broken into fine powder, sieves, behind the mixing, granulation, during capsule processing technology routinely incapsulates, every capsules loading amount is 0.35 gram, promptly gets capsule.
Claims (4)
1. a Chinese medicine preparation for the treatment of stomachache is characterized in that: the Chinese medicine preparation that it is made by Caulis Kadsurae Longipedunculatae, Fructus cinnamomi camphorae, Radix Cynanchi Paniculati, Fructus Evodiae, Radix Tinosporae, Rhizoma Bistortae Six-element Chinese medicine; Each Chinese medicine of distinguishing the flavor of is respectively by weight: Caulis Kadsurae Longipedunculatae 30-50 part, Fructus cinnamomi camphorae 35-60 part, Radix Cynanchi Paniculati 5-15 part, Fructus Evodiae 5-15 part, Radix Tinosporae 3-15 part, Rhizoma Bistortae 3-15 part.
2. according to the Chinese medicine preparation of the described treatment stomachache of claim 1, it is characterized in that: each Chinese medicine of distinguishing the flavor of is respectively by weight: 40 parts of Caulis Kadsurae Longipedunculatae, 47 parts of Fructus cinnamomi camphoraes, 10 parts of Radix Cynanchi Paniculatis, 10 parts of Fructus Evodiaes, 8 parts of Radix Tinosporaes, 8 parts of Rhizoma Bistortaes.
3. according to the Chinese medicine preparation of the described treatment stomachache of claim 1, it is characterized in that: described Chinese medicine preparation is a said dosage form on any pharmaceutics.
4. according to the Chinese medicine preparation of claim 1 or 3 described treatments stomachache, it is characterized in that: described Chinese medicine preparation is a capsule, and the Chinese medicine powder of soon respectively distinguishing the flavor of is broken into fine powder, gets product after incapsulating according to the processing technology of conventional capsule behind the mixing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006102008802A CN100488534C (en) | 2006-09-18 | 2006-09-18 | Chinese medicine preparation for treating gastrosia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006102008802A CN100488534C (en) | 2006-09-18 | 2006-09-18 | Chinese medicine preparation for treating gastrosia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1935212A true CN1935212A (en) | 2007-03-28 |
| CN100488534C CN100488534C (en) | 2009-05-20 |
Family
ID=37953072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006102008802A Active CN100488534C (en) | 2006-09-18 | 2006-09-18 | Chinese medicine preparation for treating gastrosia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100488534C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552496A (en) * | 2010-12-16 | 2012-07-11 | 贵州万胜药业有限责任公司 | Quality detection method of compound stomachache treating capsules |
| CN108836961A (en) * | 2018-05-08 | 2018-11-20 | 贵州万胜药业有限责任公司 | A kind of Chinese medicine composition for treating stomachache |
| CN116270489A (en) * | 2023-03-22 | 2023-06-23 | 遵义市中医院 | Ginger stomach-activating granule and preparation method thereof |
-
2006
- 2006-09-18 CN CNB2006102008802A patent/CN100488534C/en active Active
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552496A (en) * | 2010-12-16 | 2012-07-11 | 贵州万胜药业有限责任公司 | Quality detection method of compound stomachache treating capsules |
| CN108836961A (en) * | 2018-05-08 | 2018-11-20 | 贵州万胜药业有限责任公司 | A kind of Chinese medicine composition for treating stomachache |
| CN108836961B (en) * | 2018-05-08 | 2021-02-12 | 贵州万胜药业有限责任公司 | Traditional Chinese medicine composition for treating stomachache |
| CN116270489A (en) * | 2023-03-22 | 2023-06-23 | 遵义市中医院 | Ginger stomach-activating granule and preparation method thereof |
| CN116270489B (en) * | 2023-03-22 | 2023-09-08 | 遵义市中医院 | Ginger stomach-activating granule and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100488534C (en) | 2009-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102698123B (en) | Traditional Chinese medicinal composition for treating transmissible gastroenteritis of swine, feed, preparation method and application thereof | |
| CN112353855A (en) | Application of traditional Chinese medicine composition in preparation of medicine for adjuvant therapy of novel coronavirus pneumonia | |
| CN102028795B (en) | Chinese pulsatilla root granules for preventing and treating livestock and poultry bacterial diseases and preparation method and premix thereof | |
| CN100488534C (en) | Chinese medicine preparation for treating gastrosia | |
| CN101209330A (en) | Compound Chinese medicinal granule with heat-clearing and detoxication, worm-expelling and liver-protecting efficacy | |
| CN101314004B (en) | Medicament for treating gynaecologic urinary system infection contamination and preparation method thereof | |
| CN102370884B (en) | Chinese medicinal composition for treating epigastric pain and preparation method thereof | |
| CN101049345B (en) | A preparation for treating disease of oral cavity and gorge, and preparation method | |
| CN106420955A (en) | Traditional Chinese medicine composition with blood glucose reduction assistance effect, preparation method and product of traditional Chinese medicine composition | |
| CN108836961B (en) | Traditional Chinese medicine composition for treating stomachache | |
| CN111481638A (en) | Traditional Chinese medicine enema preparation for treating ulcerative colitis and preparation method thereof | |
| CN104147544A (en) | Traditional Chinese medicinal composition for treating chronic anal cryptitis | |
| CN104840581B (en) | It is a kind of to be used to treat slow Chinese veterinary medicinal composition of sow prolonged lochia, heat and preparation method thereof | |
| CN103156961B (en) | Medicine composition used for treating common cold, wind cold, and lung and stomach heat stagnation | |
| CN104740068A (en) | Traditional Chinese medicine for treating accumulated damp heat chronic pelvic inflammation and preparation method thereof | |
| CN114617924B (en) | Composition for treating type 2 diabetes | |
| CN108498655A (en) | It is a kind of to be used for clearing heat and detoxicating blue gold oral solution and preparation method thereof | |
| CN110123977B (en) | Traditional Chinese medicine composition for treating diabetes combined with gout by external application | |
| CN103330824A (en) | Mongolian medicament for treating liver injury | |
| CN116726083B (en) | Traditional Chinese medicine composition for treating chronic prostatitis | |
| CN103638330B (en) | One treats migrainous Chinese medicine preparation of QIXUELIANGXU type and preparation method thereof | |
| CN1301125C (en) | Medicine for treating gastrointestinal tract disease | |
| CN1221278C (en) | A method for preparing NAOAN preparation for treating apoplexy and migraine | |
| Bitawha et al. | Herbal treatment of malaria—four case reports from the Rukararwe Partnership Workshop for Rural Development (Uganda) | |
| CN109939176B (en) | A Chinese medicinal composition for treating diabetes, and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Chinese medicine preparation for treating gastrosia Effective date of registration: 20170105 Granted publication date: 20090520 Pledgee: Bank of Guiyang Limited by Share Ltd. Zunyi branch Pledgor: Guizhou Wansheng Pharmaceutical Co.,Ltd. Registration number: 2017990000004 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200305 Granted publication date: 20090520 Pledgee: Bank of Guiyang Limited by Share Ltd. Zunyi branch Pledgor: Guizhou Wansheng Pharmaceutical Co.,Ltd. Registration number: 2017990000004 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Chinese medicine preparation for treating gastrosia Effective date of registration: 20200306 Granted publication date: 20090520 Pledgee: Zunyi Honghuagang sub branch of Bank of Guiyang Co.,Ltd. Pledgor: Guizhou Wansheng Pharmaceutical Co.,Ltd. Registration number: Y2020450000008 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221122 Granted publication date: 20090520 Pledgee: Zunyi Honghuagang sub branch of Bank of Guiyang Co.,Ltd. Pledgor: Guizhou Wansheng Pharmaceutical Co.,Ltd. Registration number: Y2020450000008 |